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Ikaros DNA-binding proteins are critical for the
development of lymphocytes and other hema-
topoietic lineages, but it remains unclear how
they cooperate with other regulators of signal-
ing and transcription to achieve ordered gene
expression during development. Here, we
show that Ikaros proteins regulate the pre-
BCR component l5 in a stage-specific manner.
In pre-BI cells, Ikaros modulated l5 expression
in competition with the transcriptional activator
EBF. This required Ikaros binding to the Igll1
(l5) promoter and was abolished either by mu-
tation of the Ikaros DNA-binding domain or by
deletion of a single Ikaros site from the Igll1 pro-
moter. At the transition from the pre-BI to pre-
BII stage, the expression of the Ikaros family
member Aiolos was upregulated and required
for the efficient silencing of Igll1. Aiolos expres-
sion was controlled by pre-BCR signals via the
adaptor protein SLP-65. Thus, pre-BCR signal-
ing regulates Aiolos and the silencing of Igll1 via
a developmental-stage-specific feedback loop.
INTRODUCTION
Like theDrosophila protein hunchback, Ikaros proteins are
characterized by a highly conserved C2H2 zinc finger
DNA-binding domain near the N terminus and a C2H2
zinc finger protein-protein interaction domain near the
C terminus, which mediates the formation of dimers and
multimers between Ikaros family members (Georgopoulos
et al., 1992; Hahm et al., 1994). In mouse and humans, the
Ikaros family has five members. Pegasus and Eos arebroadly expressed, whereas Ikaros, Aiolos, and Helios
are restricted to hematopoietic cells. Ikaros, Aiolos, and
Helios bind similar or identical DNA sequences, and their
specific roles at successive stages of hematopoiesis
are incompletely defined (reviewed by Georgopoulos
[2002]; Cobb and Smale, 2005). Ikaros-deficient mice
lack B cells and show retarded T cell development and
perturbed myelopoiesis (Wang et al., 1996), whereas
Aiolos deficiency results in abnormal B cell development
and function (Wang et al., 1998). Deletion of the Ikaros
DNA-binding domain results in the absence of detectable
lymphocytes or their precursors (Georgopoulos et al.,
1994). Additional functions in erythroid and myeloid devel-
opment were revealed by an allele encoding a dominant-
negative Ikaros protein, which no longer binds DNA but
dimerizes with other Ikaros family members and thereby
inhibits their function (Papathanasiou et al., 2003). Ikzf1
(Ikaros) hemizygous mice have abnormal T and B cell
function and develop T cell malignancies (reviewed by
Georgopoulos [2002]).
Ikaros proteins can transactivate (Molnar and Georgo-
poulos, 1994; Sun et al., 1996) or repress reporter plas-
mids in transient transfection assays (Koipally et al.,
1999; Koipally and Georgopoulos, 2000) and have been
linked to both the activation (Harker et al., 2002) and the
repression (Trinh et al., 2001; Sabbattini et al., 2001) of en-
dogenous genes (reviewed by Georgopoulos [2002];
Cobb and Smale, 2005). These activities have been corre-
lated with the ability of Ikaros to interact with chromatin
modifiers, including the transcriptional repressors Sin3,
CtBP, and Mi-2, a component of the NuRD histone deace-
tylase complex (Georgopoulos, 2002; Kim et al., 1999).
Ikaros accumulates at pericentromeric heterochromatin
(Brown et al., 1997) where it colocalizes with inactive
genes (Brown et al., 1997, 1999). Although this could
suggest a role in gene silencing, transcriptional activators
of the C/EBP family also localize to pericentromericImmunity 26, 335–344, March 2007 ª2007 Elsevier Inc. 335
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evidence for a role of the Ikaros family in gene silencing
comes from the mutagenesis of Ikaros-binding sites in
two putative Ikaros target genes, Dntt (Tdt, Trinh et al.,
2001) and Igll1 (l5; Sabbattini et al., 2001). One of the
two Ikaros sites in the D’ element of the Dntt promoter
overlaps with an Ets site, so that Ikaros and Ets proteins
cannot bind the D’ element simultaneously. Mutations
that disrupt Ikaros binding to the Dntt D’ element prevent
the appropriate downregulation of promoter activity in
response to stimulation of the T cell receptor in stable
transfection assays (Trinh et al., 2001). Similarly, the Igll1
promoter has two Ikaros sites, designated Ik1 and Ik2.
Embedded in the Ik1 site is an EBF site, which is required
for full promoter activity (Martensson and Martensson,
1997). Deletion of the Ik2 site from a 12 kb Igll1-Vpreb1 ge-
nomic fragment in a transgenic mouse assay resulted in
the inappropriate expression of Igll1 in a fraction of mature
B cells (Sabbattini et al., 2001).
Although these data show that Ikaros sites are impor-
tant for the negative regulation of both the Igll1 and the
Dntt promoter, it remains unclear how the repressive
potential of Ikaros-family proteins is harnessed during
development to allow the stage-specific expression and
silencing of target genes. To address this question, we
have explored the effects of wild-type and dominant-
negative Ikaros proteins on the developmental regulation
of the Igll1 locus in the B cell lineage. B cell development
is divided into distinct stages based on the expression of
marker genes, the pre-B cell receptor (pre-BCR) compo-
nents Igll1 and Vpreb1, and the rearrangement of immu-
noglobulin (Ig) genes (reviewed by Melchers et al. [2000];
Jumaa et al., 2005). Pre-BI cells (CD43+ c-kit+ CD25)
express Igll1, Vpreb1, Rag, and Dntt but lack productive
V-DJH (heavy) chain rearrangements and a functional
pre-BCR. Successful V-DJH rearrangement and pre-
BCR expression initiate the transition from the pre-BI to
the pre-BII stage (CD43 c-kit CD25+). Pre-BCR signal-
ing results in cell-cycle entry and a transient phase of pro-
liferation—described here as the large pre-BII cell stage.
Subsequently, the pre-BCR is downregulated, and pre-
BII cells drop out of cycle to initiate immunoglobulin
light-chain rearrangement. The progression to this stage,
referred to as the small pre-BII stage, and the termination
of pre-BCR signaling require the adaptor proteins SLP-65
(also known as BLNK or BASH) and LAT (Jumaa et al.,
2005). In the absence of SLP-65, pre-BII cells proliferate
extensively and fail to downregulate the pre-BCR compo-
nents Igll1 and Vpreb1, as well as Rag and Dntt (reviewed
by Jumaa et al. [2005]). The transcription factors IRF4 or
the closely related IRF8 contribute to the downregulation
of pre-BCR components in response to pre-BCR signals
(Lu et al., 2003). Because SLP-65 expression is normal
in the absence of IRF4 and IRF8, IRFs are considered as
downstream targets of SLP-65, but upstream of Igll1
(Jumaa et al., 2005; Lu et al., 2003). Here, we show how
Ikaros family members control Igll1 expression in a devel-
opmental-stage-specific manner. In pre-BI cells, the ex-
pression of Igll1 is set by the balance between Ikaros336 Immunity 26, 335–344, March 2007 ª2007 Elsevier Inc.and the transcriptional activator EBF. At the transition
from the pre-BI to the pre-BII stage, the Ikaros family
member Ikzf3 (Aiolos) is sharply upregulated and required
for the appropriate silencing of Igll1. The expression of
Ikzf3 is controlled by SLP-65, which places Aiolos into
a feedback loop that mediates the transcriptional silenc-
ing of pre-BCR components in response to pre-BCR sig-
naling during B cell development. Upregulation of Aiolos
results in increased occupancy of the Igll1 promoter. Gel
mobility-shift experiments show mutually exclusive bind-
ing of Ikaros proteins and EBF to the Igll1 promoter, pro-
viding a mechanism for the developmentally regulated
silencing of l5 expression.
RESULTS
Regulation of the Endogenous Igll1 Locus
by Ikaros in Pre-B Cells
To examine the role of Ikaros in the regulation of the Igll1
locus, we transduced the pre-B cell line B3 (Brown et al.,
1997) with mouse stem cell virus (MSCV) retroviral vectors
encoding full-length Ikaros tagged with a hemagglutinin
(HA) epitope followed by an internal ribosomal entry site
(IRES) and enhanced green fluorescent protein (Ikaros-
IRES-GFP; Cobb et al., 2000). Immunoblot analysis
showed that sorted GFP-positive cells expressed approx-
imately five to ten times more Ikaros than B3 cells trans-
duced with the IRES-GFP control vector (Figure 1A). By
using GFP as an indicator of Ikaros-IRES-GFP expression,
we examined log GFP versus log l5 expression in individ-
ual cells by flow cytometry (Figure 1A). l5 expression was
inversely correlated with Ikaros-IRES-GFP, and l5 protein
expression in Ikaros-IRES-GFPhi B3 cells was reduced to
10% of l5 protein expression in IRES-GFPhi control cells
(Figure 1A).
We extended these observations to primary pre-B cells
cultured with IL-7 on S17 stromal cells (see Experimental
Procedures). Immunoblotting showed that primary pre-B
cells transduced with Ikaros-IRES-GFP expressed 2-3
fold more Ikaros than the controls (Figure 1B). Intracellular
staining demonstrated that this moderate increase in
Ikaros expression was sufficient for causing a proportional
reduction in l5 protein expression (Figure 1C). Real-time
RT-PCR analysis showed a corresponding reduction of
Igll1 transcripts (Figure 1C), although the expression of
the cell-surface proteins CD19 and B220 and the house-
keeping genes Ube, B2m, and Ywhaz was not significantly
altered (data not shown). In contrast to Igll1, Dntt expres-
sion was not affected by 2- to 3-fold Ikaros overexpres-
sion (Figure 1C).
Ikaros Regulation of Igll1 Expression in the Absence
of Pre-BCR Signals
Because most pre-B cells cultured on stroma with IL-7
have no functional IgH rearrangements (Melchers et al.,
2000 and data not shown), these data suggest that Ikaros
regulates Igll1 expression at the pre-BI cell stage indepen-
dently of pre-BCR signals. To address this point formally,
we used Rag1/ pro-B cells, which cannot rearrange
Immunity
Stage-Specific Regulation of an Ikaros Target GeneFigure 1. Ikaros Regulates Igll1 Expression in Pre-B Cells Prior to Pre-B Cell Receptor Signaling
(A) B3 pre-B cells were infected with either retroviral vectors encoding HA-tagged full-length Ikaros followed by an internal ribosomal entry site (IRES)
sequence and GFP (Ikaros-IRES-GFP) or the control vector (IRES-GFP). GFP+ cells were sorted by flow cytometry 72 hr later and Ikaros protein ex-
pression was estimated by immunoblotting. TBP served as a loading control. Intracellular staining and flow cytometry showed that log l5 expression
was inversely proportional to log GFP expression in Ikaros-IRES-GFP-transduced B3 pre-B cells. The bar graph summarizes l5 protein expression in
GFPhi B3 cells (boxed) transduced with Ikaros-IRES-GFP relative to the control IRES-GFP vector. An additional band of 47 kDa (*) does not account
for the effects of full-length Ikaros because it was also seen in cells transduced with 159A Ikaros (see below).
(B) Primary pre-B cells were infected with retroviral vectors encoding HA-tagged full-length Ikaros (Ikaros-IRES-GFP) or the control vector (IRES-
GFP). GFP+ cells were sorted by flow cytometry 72 hr later. Ikaros-IRES-GFP transduced cells expressed 2- to 3-fold more Ikaros isoform 1 than
control cells.
(C) Intracellular staining and flow cytometry were used for determining l5 protein expression in CD19+ GFP+ primary pre-B cells transduced with
Ikaros-IRES-GFP or the control IRES-GFP vector. Histogram overlays show log l5 staining intensity versus cell number; the bar graph summarizes
l5 protein expression in cells transduced with Ikaros-IRES-GFP relative to the control IRES-GFP vector (mean ± SD, n = 3). Igll1 (l5) and Dntt1 RNA
expression in sorted CD19+ GFP+ primary pre-B cells transduced with Ikaros-IRES-GFP or the control IRES-GFP vector was determined by real-time
RT-PCR.
(D) Primary Rag1/ pro-B cells were transduced with Ikaros-IRES-GFP or the control IRES-GFP vector, and sorted CD19+ GFP+ cells were analyzed
for l5 protein and Igll1 RNA expression as in Figure 1 (mean ± SE, n = 2).Ig-H and therefore lack pre-BCR expression. Rag1/
pro-B cells downregulated Igll1 just like wild-type cells
when transduced with Ikaros-IRES-GFP (Figure 1D).
Hence, Ikaros affects the expression of Igll1 prior to and
independently of pre-BCR signaling.
Igll1 Repression by Ikaros Requires a Functional
Ikaros DNA-Binding Domain and the Presence of
Intact Ikaros-Binding Sites in the Igll1 Promoter
To define the requirements for Ikaros-mediated Igll1 re-
pression, we asked whether binding of Ikaros to DNA,
specifically to sites in the Igll1 promoter, is involved. We
transduced primary pre-B cells with HA-tagged wild-
type Ikaros or the 159A mutant, which has an aspara-
gine-to-alanine substitution in the second N-terminal
zinc finger and is defective in DNA binding (Cobb et al.,
2000), as indicated by its inability to form pericentromeric
Ikaros clusters (Brown et al., 1997; Cobb et al., 2000). En-
dogenous Ikaros (detected with Ikaros antiserum, green)
and retrovirally transduced wild-type Ikaros (detected
with anti-HA, red) colocalized with DAPI-dense centro-
meric domains (Figure 2A), consistent with Ikaros binding
to high-affinity sites in pericentromeric repeats (Cobb
et al., 2000). In contrast, retrovirally transduced DNA-
binding-defective 159A Ikaros (detected with anti-HA)was distributed diffusely within nuclei and appeared ex-
cluded from the less accessible DAPI-dense regions (Fig-
ure 2A). Moreover, staining with Ikaros antiserum showed
that even moderate overexpression (approximately 2- to
3-fold, Figure 2A) of 159A resulted in a redistribution of to-
tal Ikaros protein, including endogenous Ikaros, away
from DAPI-dense regions (Figure 2A). To address whether
Ikaros affects Igll1 expression by direct interaction with
the Igll1 promoter, we combined the analysis of endoge-
nous Igll1 with that of a transgene where Igll1 expression
from a 12 kb fragment of the Igll1-Vpreb1 locus (Sabbattini
et al., 2001) is driven either by the wild-type Igll1 promoter
or by a mutated promoter lacking the Ik2 Ikaros-binding
site (Figure 2B). We transduced transgenic pre-B cells
with wild-type Ikaros-IRES-GFP, 159A-IRES-GFP, or the
IRES-GFP control vector and used real-time RT-PCR to
selectively determine the level of transcripts arising from
the endogenous Igll1 locus or the Igll1 transgene (Fig-
ure S1 in the Supplemental Data available online). Like
the endogenous Igll1 locus, the transgene driven by the
wild-type Igll1 promoter was downregulated by Ikaros
(Figure 2B). In contrast, the transgene driven by the pro-
moter lacking the Ik2 site remained fully active in Ikaros
overexpressing pre-B cells, whereas endogenous Igll1
was downregulated (Figure 2B). In contrast to wild-typeImmunity 26, 335–344, March 2007 ª2007 Elsevier Inc. 337
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Requires an Intact Ikaros DNA-Binding
Domain and the Presence of Ikaros-
Binding Sites in the Igll1 Promoter
(A) Primary pre-B cells infected with HA-
tagged wild-type Ikaros-IRES-GFP, the DNA-
binding-deficient Ikaros mutant 159A-IRES-
GFP, or control IRES-GFP were analyzed by
immunofluorescence staining and confocal mi-
croscopy 72 hr later. Ikaros antiserum (shown
in green) detects the subcellular distribution
of total Ikaros protein, whereas the HA-tag an-
tibody (shown in red) specifically detects virally
encoded HA-tagged Ikaros. Endogenous and
virally encoded wild-type Ikaros localize to
DAPI-bright domains, whereas 159A Ikaros is
diffusely distributed and results in the redistri-
bution of total Ikaros, including endogenous
protein, away from DAPI-bright regions. Trans-
duced primary pre-B cells overexpressed
159A Ikaros approximately 2- to 3-fold (similar
to wild-type Ikaros, see Figure 1A). An addi-
tional band of 47 kDa (*) does not account for
the effects of 159A Ikaros because it was also
seen in Figure 1A when cells were transduced
with full-length Ikaros.
(B) Primary pre-B cells containing transgenes
driven by the wild-type Igll1 promoter (left) or
the Igll1 promoter with a deleted Ik2 Ikaros-
binding site (del. Ik2, right) were transduced
with Ikaros-IRES-GFP, 159A-IRES-GFP, or
the IRES-GFP control vector. With the PCR
strategy outlined in Figure S1, endogenous
and transgene-encoded Igll1 transcripts were
assessed separately by real-time RT-PCR
(mean ± SE, n = 2–4).
(C) ChIP of endogenous Ikaros (with C-terminal
Ikaros antibody) in the B3 pre-B cell line. Data
for the Igll1 promoter, g-satellite repeats, and
B2m are normalized to binding at a DNaseI hy-
persensitive site 50 of the Igll1-Vpreb1 locus
(50HSS). Rabbit IgG was used as a control
(IgG; mean ± SD, n = 3).Ikaros, 159A Ikaros slightly—but reproducibly—enhanced
the expression of endogenous Igll1 and the Igll1 transgene
retaining the Ik2-binding site (Figure 2B). Consistent with
these functional data, chromatin immunoprecipitation
(ChIP) of endogenous Ikaros from B3 pre-B cells yielded
a substantial enrichment of the Igll1 promoter relative to
input and to the controls, a DNaseI hypersensitive site 50
of the Igll1-Vpreb1 locus (50HSS) and the B2m promoter
(Figure 2C). No enrichment was seen in fibroblasts, which
do not express Ikaros (data not shown).
Igll1 Expression Reflects the Balance of Ikaros
Family Proteins and EBF
Transduction of B3 pre-B cells with a retrovirus encoding
EBF and monomeric red fluorescent protein (EBF-IRES-
mRFP) but not with the IRES-mRFP control vector re-
sulted in elevated expression of Igll1 (Figure 3). EBF-338 Immunity 26, 335–344, March 2007 ª2007 Elsevier Inc.IRES-mRFP restored Igll1 expression in cells cotrans-
duced with Ikaros-IRES-GFP (Figure 3), consistent with
a scenario where EBF and Ikaros family members com-
pete with one another for binding to the Igll1 promoter
(Sabbattini et al., 2001).
The data presented so far show that Ikaros acts at the
Igll1 locus in pre-BI cells to balance l5 expression in com-
petition with transcriptional activators in pre-BI cells,
a stage of development where pre-BCR components—
including l5—are scheduled for expression and required
for normal development.
Aiolos Is Upregulated at the Transition from the
Pre-BI to the Pre-BII Stage and Is Required
for the Appropriate Silencing of Igll1
To assess the contribution of Ikaros and EBF to the regu-
lation of Igll1 at the transition from the pre-BI to the pre-BII
Immunity
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pre-BII (CD43 B220int IgMneg) cells from bone marrow.
As expected, l5 protein and Igll1 mRNA were downregu-
lated in pre-BII relative to pre-BI cells, although Ebf1 and
Ikzf1 (Ikaros) expression were comparable between these
populations (Figure 4A). Aiolos expression is reported
to be low in B lineage cells prior to IgH rearrangement
(Morgan et al., 1997). Interestingly, we found a substantial
increase in Ikzf3 (Aiolos) RNA and protein expression as
pre-BI cells transit to the pre-BII stage (Figure 4A).
To address the potential role of Aiolos in the downregu-
lation of Igll1 at the transition from the pre-BI to the pre-BII
stage, we assessed Igll1 expression at successive stages
of B cell development in control and Aiolos-deficient mice.
B cell development in the absence of Aiolos has been
shown to progress relatively normally (Wang et al.,
1998), and this allows a direct comparison among pre-
BI, large (early) pre-BII, and small (late) pre-BII cells (Fig-
ure 4B). In cells from control mice, real-time RT-PCR
showed a substantial reduction of Igll1 transcripts be-
tween the pre-BI and the large pre-BII stage. A further
substantial reduction in Igll1 transcripts occurred between
the large and small pre-BII cell stage (Figure 4B). In the ab-
sence of Aiolos, Igll1 RNA expression decreased from the
pre-BI to the large pre-BII stage, but there was no further
reduction between the large and small pre-BII cell stage
(Figure 4B). Consistent with the RNA data, l5 protein
remained detectable in Aiolos-deficient pre-BII cells by
intracellular staining (data not shown). Hence, Igll1 is par-
tially downregulated, but not appropriately silenced, in the
absence of Aiolos. Retroviral reconstitution of Aiolos-defi-
cient pre-B cells with Aiolos-GFP resulted in reduced Igll1
RNA expression (Figure 4C).
Control of Aiolos Expression by SLP-65
The transition from the pre-BI to the pre-BII stage is con-
trolled by the pre-BCR, which initiates a proliferative
phase (the large pre-BII stage), later terminated by the
downregulation of cell-surface pre-BCR and the transcrip-
tional silencing of Igll1 and Vpreb1. The termination—but
not the initiation—of the proliferative phase and the down-
regulation of pre-BCR and its components require the
adaptor protein SLP-65 (reviewed by Jumaa et al.
[2005]). SLP-65-deficient pre-B cells proliferate in re-
sponse to pre-BCR signals and are unable to terminate
pre-BCR signaling until the expression of SLP-65 is re-
stored. Our finding that Aiolos is required for the efficient
silencing of Igll1 tentatively places Aiolos expression in
the termination phase before BCR signaling. In this sce-
nario, Aiolos expression would be expected to occur after
the initiation of pre-BCR signaling and to precede its ter-
mination. Consistent with this idea, SLP-65-deficient
mice failed to increase Aiolos expression between the
CD43+ B220low IgMneg and the CD43 B220int IgMneg
stage of B cell development (data not shown). To test
the role of SLP-65 in regulating Aiolos more directly, we
evaluated Aiolos expression in SLP-65-deficient pre-B
cells that were stably transfected with a tamoxifen-induc-
ible ERt2-SLP-65 fusion protein or an ERt2-GFP controlconstruct. The cells were treated with 4-hydroxy-tamoxi-
fen, and the expression of relevant transcripts assessed
by real-time RT-PCR. SLP-65 reconstitution induced the
upregulation of Aiolos RNA, reaching 3-fold 8 hr after the
addition of 4-hydroxy-tamoxifen (Figure 5A). In contrast
to Aiolos, Ikaros expression remained unchanged (data
not shown). Igll1 RNA expression was reduced by 4–8 hr
after SLP-65 induction and continued to decline for at
least 24 hr (Figure 5A). IRF4 is a putative target of SLP-
65 (Jumaa et al., 2005; Lu et al., 2003), and Irf4 RNA
was upregulated 4-fold by 1 hr, and expression peaked
4 hr after SLP-65 induction (Figure 5A).
To ask whether the increased Aiolos expression result-
ing from the reconstitution of SLP-65 in SLP-65-deficient
pre-B cells was reflected in Aiolos occupancy of the Igll1
promoter, we carried out Aiolos ChIP and found increased
binding to the Igll1 promoter (Figure 5B). Mechanistically,
the downregulation of Igll1 after SLP-65 reconstitution
could result from competition between Ikaros proteins
and EBF for binding to the Igll1 promoter. To address
this possibility, we carried out gel mobility-shift assays
where the binding of HA-tagged Ikaros and FLAG-tagged
EBF to a double-stranded probe, which comprised both
Ikaros sites and the EBF site within the Igll1 promoter
(71 to 128, Sabbattini et al., 2001). HA-Ikaros and
FLAG-EBF formed complexes of distinct mobility (Fig-
ure 5C, first panel). Addition of both HA-Ikaros and
FLAG-EBF did not result in additional complexes, and
titration of HA-Ikaros to a fixed amount of FLAG-EBF
reduced the amount of EBF complex formed. Taken to-
gether, these data are consistent with a scenario where
Ikaros proteins and EBF compete for binding to the Igll1
promoter (Figure 5C, first panel). Substitution of DNA-
binding-defective 159A Ikaros for wild-type Ikaros
abrogated competition with EBF, demonstrating that
competition between Ikaros and EBF in this assay occurs
Figure 3. Ikaros-Family Proteins and EBF Balance l5 Expres-
sion in Pre-B Cells
B3 cells were transduced with the indicated combinations of Ikaros-
IRES-GFP (or IRES-GFP, vector) and EBF-IRES-mRFP (or IRES-
mRFP, vector). Cells expressing both GFP and mRFP were sorted
and analyzed for l5 protein expression by intracellular staining
(mean ± SE, n = 2). Note that EBF rescues l5 expression in Ikaros over-
expressing pre-B cells.Immunity 26, 335–344, March 2007 ª2007 Elsevier Inc. 339
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Stage-Specific Regulation of an Ikaros Target GeneFigure 4. Aiolos Is Upregulated at the Transition from the Pre-BI to the Pre-BII Stage andRequired for the Efficient Silencing of Igll1
(A) Primary pre-BI (CD43+B220lowIgM) and pre-B II (CD43B220intIgM) from bone marrow were analyzed for l5 expression by intracellular staining
(histogram). Bone marrow pre-BI and pre-B II cells were sorted, and Igll1, Ebf1, Ikzf1 (Ikaros), and Ikzf3 (Aiolos) RNA expression was determined
by real-time RT-PCR. Aiolos protein expression was determined by immunoblotting. Note the sharp upregulation of Aiolos between the pre-BI
and pre-BII cell stage.
(B) Pre-BI, large pre-BII (high-forward scatter), and small pre-BII cells (low-forward scatter) were sorted from wild-type and Aiolos-deficient mice, and
Igll1 expression was assessed by real-time RT-PCR.
(C) Primary Aiolos-deficient pre-B cells were transduced with Aiolos-IRES-GFP or the control IRES-GFP vector. Sorted GFP+ cells were analyzed for
Igll1 RNA expression as in Figure 1 (mean ± SD, n = 3).at the level of DNA binding (Figure 5C, second panel). EBF
and Ikaros complexes were specifically affected (depleted
or supershifted) by HA and FLAG antibodies, respectively,
even when HA-Ikaros and FLAG-EBF were present in the
same reaction (Figure 5C, right-hand panels).
Taken together, these data suggest a working model for
the transition, from the pre-BI to the pre-BII stage, where
pre-BCR signaling feeds back to silence the expression of
the pre-BCR component l5 via SLP-65, IRF4, and Aiolos
(Figure 6).340 Immunity 26, 335–344, March 2007 ª2007 Elsevier Inc.DISCUSSION
We have shown that Ikaros proteins mediate the develop-
mental-stage-specific regulation of endogenous Igll1 ex-
pression in developing B cells. This is accomplished in
two discrete steps, resulting in the balanced expression
of l5 in pre-BI cells and its silencing in pre-BII cells,
respectively.
In pre-BI cells, Igll1 expression driven by EBF and other
transcriptional activators (Martensson and Martensson,
Immunity
Stage-Specific Regulation of an Ikaros Target GeneFigure 5. The Upregulation of Aiolos at the Transition from the Pre-BI to the Pre-BII Stage Is Controlled by SLP-65
(A) SLP-65-deficient pre-B cells expressing a tamoxifen-inducible ERt2-SLP-65 fusion protein or an ERt2-GFP control construct were treated with
4-hydroxy-tamoxifen, and Ikzf3 (Aiolos), Igll1 (l5), and Irf4 RNA expression was determined by real-time RT-PCR (mean ± SD, n = 4).
(B) ChIP of endogenos Aiolos in SLP-65-deficient pre-B cells before and after activation of ERt2-SLP-65 by 4-hydroxy-tamoxifen. Data (mean ± SD,
n = 3) for a DNaseI hypersensitive site located at the 50 end of the Igll1-Vpreb1 locus (50HSS), the Igll1 promoter, and theB2m promoter are normalized
to binding at the Igll1 promoter before SLP-65 reconstitution. Rabbit IgG was used as a control (IgG).
(C) Gel mobility-shift assay showing the binding of HA-tagged Ikaros and FLAG-tagged EBF to a double-stranded DNA probe comprising both Ikaros
sites and the EBF site within the Igll1 promoter (71 to 128). The total amount of extract in each lane was kept constant by an addition of the control
extract. The positions of Ikaros and EBF complexes are shown; asterisks mark a nonspecific band. Instead of wild-type Ikaros, 159A Ikaros was used
for demonstrating that DNA binding is required for competition with EBF (second panel). Anti-HA and anti-FLAG were used to selectively interfere with
Ikaros and EBF complexes (right-hand panels).Immunity 26, 335–344, March 2007 ª2007 Elsevier Inc. 341
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opmental-Stage-Specific Regulation of
Igll1 (l5) in Pre-BI Cells and in Response
to Pre-BCR Signaling during the Transi-
tion from the Pre-BI to the Pre-BII Stage
Pre-BCR signals result in the SLP-65-depen-
dent upregulation of IRF4 and Aiolos, which,
along with other factors, contribute to the
silencing of Igll1. Arrows do not imply direct
or exclusive interactions.1997; Jumaa et al., 2005) appears to be balanced by
Ikaros proteins via DNA binding to sites in the Igll1 pro-
moter because (1) transduction of pre-BI cells wild-type
and DNA-binding-deficient (159A) Ikaros results in re-
duced and elevated Igll1 RNA expression, respectively,
and (2) ChIP analysis shows the presence of Ikaros protein
at the Igll1 promoter in pre-BI cells. The finding that Ikaros
cooperates with transcriptional activators to define the ac-
tivity of the Igll1 promoter adds a new angle to the discus-
sion whether Ikaros acts in gene silencing versus activa-
tion (Georgopoulos, 2002; Cobb and Smale, 2005).
Expression of the pre-BCR initiates a sequence of
events including the selective clonal expansion of pre-B
cells with successful IgH rearrangements and the transi-
tion from the pre-BI to the large pre-BII stage. Aiolos
RNA and protein expression are sharply upregulated at
the transition from the pre-BI to the pre-BII stage. Analysis
of Aiolos-deficient developing B cells shows that in the ab-
sence of Aiolos, Igll1 is only partially downregulated but
not efficiently silenced as in wild-type cells. This suggests
that Aiolos, although required for the appropriate silencing
of Igll1 in pre-BII cells, it is not the only factor contributing
to Igll1 silencing.
Increased Aiolos expression results in increased occu-
pancy of the Igll1 promoter. Gel mobility-shift assays pro-
vide a mechanistic explanation for the reduced expression
of Igll1 by demonstrating that the binding of Ikaros pro-
teins and EBF to the Igll1 promoter is mutually exclusive.
This is consistent with the organization of the Igll1 pro-
moter because the binding site for EBF overlaps with
one of two tandem Ikaros sites (Ik1 in Sabbattini et al.,
2001). Precedent for such competition comes from the
regulation of hox genes in Drosophila, where the Ikaros-
related Hunchback protein competes for DNA binding
with transcriptional activators (Lawrence, 1992). Overlap
between sites for transcriptional activators and Ikaros is
found at other promoters. The Dntt promoter has two
Ikaros sites, one of which overlaps with a site for Ets-fam-
ily transcriptional activators. Whereas the Ets site is critical
forDntt promoter activity, both Ikaros sites are required for
the downregulation of Dntt promoter activity in the VL3
thymocyte cell line in response to T-cell-receptor engage-
ment or stimulation with phorbol ester and Ca2+ ionophore
(Trinh et al., 2001). Given the arrangement of binding sites
for Ikaros and transcriptional activators (Sabbattini et al.,342 Immunity 26, 335–344, March 2007 ª2007 Elsevier Inc.2001; Trinh et al., 2001), it was surprising that Dntt expres-
sion was barely affected by retroviral expression of Ikaros
in pre-BI cells (this study) and in double-positive thymo-
cytes (E.T. and M.M., unpublished data). We speculate
that Dntt downregulation requires—in addition to Ikaros
proteins (Trinh et al., 2001)—other factors, which are pro-
vided by lymphocyte receptor signaling.
Beyond competition, increased occupancy by Ikaros
proteins may result in the recruitment of chromatin modi-
fiers, in particular histone deacetylases (Kim et al., 1999;
Koipally et al., 1999). Consistent with this prediction,
loss of histone H3 and H4 acetylation and H3K4 methyla-
tion have been reported for the silenced Igll1 locus (Szu-
torisz et al., 2005). Silencing of Igll1 is not accompanied
by DNA (CpG) methylation, delayed replication in S phase
(Azuara et al., 2003), or a drastic reduction in chromatin
accessibility (Sabbattini et al., 2001) but with repositioning
to the vicinity of pericentromeric heterochromatin (Brown
et al., 1997). Ikaros proteins may contribute to this reposi-
tioning because they bind to high-affinity sites in pericen-
tromeic g-satellite repeats (Cobb et al., 2000) and silenc-
ing involves increased Aiolos occupancy of the Igll1
promoter (this paper).
Most important for our understanding of gene regulation
during B cell development is the finding that the expres-
sion of Aiolos itself is controlled by pre-BCR signaling,
via SLP-65. SLP-65 is required for the termination of
pre-BCR signaling, cessation of proliferation, transition
from the large to the small pre-BII stage, and the shutdown
of the pre-BCR components l5 and Vpreb1 (Melchers
et al., 2000; Jumaa et al., 2005). Our data suggest that Aio-
los forms an integral part of this developmental transition
and thereby place Aiolos into a developmental-stage-
specific feedback loop that links signaling through the
pre-BCR to the transcriptional silencing of Igll1, the gene
encoding the pre-BCR component l5. These results begin
to integrate the regulatory potential of Ikaros-family pro-
teins into a biologically meaningful context.
EXPERIMENTAL PROCEDURES
Cells and Tissue Culture
The pre-B cell line B3 has been described (Brown et al., 1997). Primary
pre-B cells were established from BALB/c, Rag1/ (Spanopoulou
et al., 1995) Igll1-Vpreb1 transgenic (Sabbattini et al., 2001), or
Immunity
Stage-Specific Regulation of an Ikaros Target GeneAiolos-deficient (Wang et al., 1998) mice in accordance with the Ani-
mals (Scientific Procedures) Act under Project Licences granted by
the Home Office, UK. E14.5 fetal liver cells were plated on irradiated
S17 stromal cells in IMDM, 10% FCS, 1% penicillin-streptomycin,
2 mM 2-mercaptoethanol, and 5 ng/ml IL-7. Where indicated, cells
were transduced with MSCV-based retroviral constructs (Cobb
et al., 2000). SLP-65-deficient pre-B cells (Jumaa et al., 2001) were
transduced with a construct encoding a fusion protein of SLP-65
and the estrogen receptor hormone-binding domain (ERt2-SLP-65-
IRES-GFP), or a ERt2-IRES-GFP control construct (S.M., F. Ko¨hler,
T. Wossning, M. Reppel, M. Mu¨schen, and H.J., unpublished data).
Cells were treated with 4-hydroxy-tamoxifen for the indicated times.
Immunofluorescence Staining, Microscopy,
and Flow Cytometry
CD19-PE or B220-PE, CD43-FITC (Pharmingen), and IgM-Cy5 (Caltag)
were used for surface staining. Intracellular staining for l5-biotin (Phar-
mingen) and SA-TC (Caltag) was done with a Cytofix/Cytoperm kit
(Pharmingen). Cells were analyzed and sorted with FACSCalibur,
FACSDiva, and FACSAria instruments (Beckton Dickinson). Immuno-
fluorescence staining and microscopy have been described (Baxter
et al., 2004) with rabbit anti-C-terminal Ikaros (Cobb et al., 2000),
anti-HA-TRTC (Santa Cruz Biotechnology), and goat anti-rabbit
Ig-Cy5 (Jackson Immunoresearch Laboratories).
Immunoblotting
Ikaros was detected with rabbit anti-C-terminal Ikaros antibody. Rab-
bit anti-TBP (the kind gift of Dr L. Tora, Strasbourg, France) was used
as a loading control.
Real-Time RT-PCR
Total RNA was isolated with RNAbee (Tel-Test) and reverse tran-
scribed. PCR reactions included 23 SYBR PCR Master Mix (Qiagen),
300 nM primers, and 2 ml of cDNA as a template in 50 ml reaction vol-
ume. Cycle conditions were 94 C for 8 min, 40 cycles of 94 C for 30 s,
55 C for 30 s, and 72 C for 1 min, and this was followed by a plate
read. All primers used amplified specific cDNAs with an efficiency of
>95%. mRNA content was normalized to the geometrical average of
two housekeeping genes, Ywhaz, B2m, and Ube with the CT method
as outlined in the Applied Biosystems protocol for reverse transcrip-
tase-PCR. Primer sequences were as follows:
Ywhaz fw 50-CGTTGTAGGAGCCCGTAGGTCAT-30 rev 50-TCTGG
TTGCGAAGCATTGGG-30
Ube fw 50-AGGAGGCTGATGAAGGAGCTTGA-30 rev 50-TGGTTTG
AATGGATACTCTGCTGGA-30
Dntt fw 50-GGGTTCAGGGTGGAAAATGAGC-30 rev 50-TGAGCCA
GGAGATGTCCAAGAG-30
Endogenous Igll1 fw 50-ACAGCAGACCAACCGGTGGAA-30 rev
50-ACTGGAACGGGCGTTCGC-30
Transgenic Igll1 fw 50-AAAGCTGATTTCTGAGGAGGATCTGGA-30
rev 50-GTGGGATGATCTGGAACAGGAG-30
Ebf1 fw 50-AGATCTGGTTGAAGCCCTGTATGG-30 rev 50-CATGTC
ACATCTCAGATCCTGTGTTCT-30
Ikzf1 fw 50-TCGGGAGAGAAAATAATGG-30 rev 50-AGGCCGTTCA
CCAGTATGAC-30
Ikzf3 fw 50-ACAGCAGACCAACCGGTGGGAA-30 rev 50-ACTGGAA
CGGGCGTTCGC-30
B2m fw 50-CACCCGCCTCACATTGAAAT-30 rev 50-TCGATCCCA
GTAGACGGTCTTG-30
Chromatin Immunoprecipitation
For Ikaros and Aiolos ChIP, cells were crosslinked at room tempera-
ture in 1 mM disuccinimidyl glutarate (Pierce) for 30 min, and this
was followed by 1% formaldehyde for 1 hr. Fixed cells were washed
three times in ice-cold PBS and resuspended in 10 mM Tris (pH 8.0)
and 3 mM MgCl2 containing protease inhibitors. Cells were disrupted
by Dounce homogenization, and the nuclei were collected in TE bufferand 1% SDS. Chromatin extracts were sonicated to an average size of
1 kb, and 10 ml C-terminal Ikaros antibody or Aiolos monoclonal anti-
body was added to 500 mg sonicated chromatin for immunoprecipita-
tion. Crosslinking was reversed in TE containing 1% SDS at 65C for
6 hr. DNA was purified by phenol-chloroform extraction and real-
time PCR was performed on 0.2 ng DNA.
Gel Mobility-Shift Assays
Nuclear extracts from 293T cells transfected with HA-Ikaros or HA-
159A Ikaros, FLAG-EBF or control vector were prepared, and gel
mobility-shift assays were performed as described (Cobb et al.,
2000) with the P32-labeled synthetic double-stranded oligonucleotide
probe 50-TCGACCAGTTAGGCTTGCATCCCAACCACAACCGGGTAG
TCCTTTGGGAGAGAACTCCACAGAG-30 corresponding to nucleo-
tides 71 to 128 of the Igll1 promoter containing both the EBF-IK1
and the IK2 site (Sabbattini et al., 2001) flanked by TCGAC at the 50
ends of both strands to facilitate labeling.
Supplemental Data
Supplemental Data include one figure and are available with this article
online at http://www.immunity.com/cgi/content/full/26/3/335/DC1/.
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